Opinion|Videos|July 9, 2024
Examining Challenges with Drug Switching and Step Therapy in MS Treatment
Key opinion leaders discuss the challenges associated with step therapy requirements after initially selecting a drug class, the patient factors considered when deciding to switch a patient with non-relapsing secondary progressive multiple sclerosis to a different therapy, and whether payers commonly employ step therapy between different drug classes.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Do you ever encounter challenges with step therapy requirements after initially selecting a drug class?
- What patient factors do you consider when deciding to switch a patient to a different therapy in patients diagnosed with non-relapsing secondary progressive multiple sclerosis?
- Are step therapies typically used for drugs within the same class, or do payers typically use step therapy between different classes of drugs?
Advertisement
Related to this article
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.
All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.
HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.
Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
2
FDA Approves First Treatment for Sanfilippo Syndrome Type A
3
Higher CPAP Adherence Linked With Lower Mortality Risk in OSA
4
Lung Cancer Progress Drives Down US Cancer Death Rates
5